Current issues with β2-adrenoceptor agonists: Historical background

Clinical Reviews in Allergy and Immunology

Volumn 31, Issue 2-3, 2006, Pages 107-117

  Tattersfield, Anne E ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Adrenaline; Epinephrine; History of 2 agonists; Isoprotenerol; 2 selectivity

Indexed keywords

ADRENALIN; ATROPINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CATECHOLAMINE DERIVATIVE; EPHEDRINE; EPHEDRINE PLUS BARBITURIC ACID; FENOTEROL; ISOETARINE; ISOPRENALINE; ORCIPRENALINE; PAPAVERINE; PHENOXYBENZAMINE; RIMITEROL; SALBUTAMOL; STRAMONIUM; TERBUTALINE; UNCLASSIFIED DRUG; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DRUG;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ANXIETY; ASTHMA; CARDIOTOXICITY; DNA POLYMORPHISM; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG RELEASE; FEAR; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HISTAMINE RELEASE; HUMAN; HYPOKALEMIA; MEDICAL LITERATURE; METERED DOSE INHALER; MORTALITY; NONHUMAN; NORADRENALIN BLOOD LEVEL; RESTLESSNESS; REVIEW; SIDE EFFECT; TACHYPHYLAXIS; ARTICLE; DRUG POTENTIATION; HISTORY;

ADRENERGIC BETA-AGONISTS; BRONCHODILATOR AGENTS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; PHARMACEUTICAL PREPARATIONS; RECEPTORS, ADRENERGIC, BETA-2;

EID: 33751318664     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1385/CRIAI:31:2:107     Document Type: Review

References (68)

1. Solis-Cohen, S. (1900), The use of adrenal substance in the treatment of asthma. JAMA 34, 1164-1166.
2. Sneader, W. (1985), Drugs affecting nervous transmission, in Drug Discovery: The Evolution of Modern Medicine. John Wiley, New York, pp. 96-126.
3. Oliver, G. and Shafer, E. A. (1894), On the physiological action of extracts of the suprarenal capsule. J. Physiol. 16, 1-4.
4. 2-Agonists in Asthma Treatment: Lung Biology in Health and Disease, vol. 106. Pauwels, R., O'Byrne, P., eds., Marcel Dekker, New York, pp.1-18.
5. Takamine, J. (1901), Adrenalin the active principle of the suprarenal gland and its mode of preparation. Am. J. Pharm. 73, 523-531.
6. Henderson, J. (2005), Ernest Starling and 'Hormones': a historical commentary. J. Endocrinol. 184, 5-10.
7. Konzett, H. (1940), Neue broncholytisch hochwirksames Korper der Adrenaline. Naunyn. Schmiederbergs. Arch. Exp. 197, 27-40.
8. Gay, L. N. and Long, J. W. (1949) Clinical evaluation of isopropyl-epinephrine in management of bronchial asthma. JAMA 12, 452-458.
9. Newman, S. P. and Clark, S. W. (1992) Inhalation devices and techniques, in Asthma 3rd ed. Clark, T. J. H., Godfrey, S. and Lee, T. H, eds.. Chapman and Hall Medical, London, pp. P469-P505.
10. Ahlquist, R. B. (1948), A study of adrenotropic receptors. Am. J. Physiol. 153, 586-600.
11. Lands, A. M., Arnold, A., McAuliff, J. P., Luduena. F. P., and Brown, T. G. (1967), Differentiation of receptor-systems activated by sympathomimetic amines. Nature 214, 597-598.
12. Paterson, J., Woolcock, A. J., and Shenfield, G. M. (1979), Bronchodilator drugs. Am. Rev. Resp. Dis. 120, 1149-1188.
13. Brittain, R. T., Dean, C. M., and Jack, D. (1981), Sympathomimetic bronchodilator drugs, in Respiratory Pharmacology. Widdicombe, J. G., ed. Oxford Pergamon, pp. 613-653.
14. Tattersfield, A. E. and McNicol, M. W. (1969), Salbutamol and isoprenaline: a double blind trial to compare bronchodilator and cardiovascular activity. N. Engl. J. Med. 281, 1323-1326.
15. Warrell, D. A., Robertson, D. G., Newton Howes, J., et al. (1970), Comparison of cardiorespiratory effects of isoprenaline and salbutamol in patients with bronchial asthma. Br. Med. J. I, 65-70.
16. Paterson, J. W., Courtney-Evans, R. J., and Prime, F. J. (1971), Selectivity of bronchodilator action of salbutamol in asthmatic patients. Brit. J. Dis. Chest. 65, 21-38.
17. 2 adrenoceptor stimulants by different modes of administration (tablets, metered aerosol and combination thereof). Am. Rev. Resp. Dis. 116, 861-869.
18. 2-adrenoceptor agonists. Eur. J. Pharmacol. 130, 97-103.
19. Wong, C. S., Pavord, I. D., Williams, J., Britton, J. R., and Tattersfield, A. E. (1990), Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 336, 1396-1399.
20. 2-agonists: mode of action and place in management, in Asthma, 4th ed. Clark, T. J. H., Godfrey, S., Lee, T. H., and Thompson, N. C. eds. New York: Arnold, London and Oxford University Press, pp. 253-282.
21. Anderson, S. D., Seale, J. P., Rozea P., Bandler, L., Theobald, G., and Lindsay, D.A., (1976), Inhaled and oral salbutamol in exercise-induced asthma. Am. Rev. Respir. Dis. 114, 493-500.
22. 2‑adrenoceptor agonists. Br. J. Clin. Pharmacol. 31, 501-514.
23. Larsson, S., Svedmyr, N., and Thiringer, G. (1977), Lack of bronchial beta-adrenoceptor resistance in asthmatics during long-term treatment with terbutaline. J. Allergy Immunol. 59, 93-100.
24. Holgate, S. T., Baldwin, C. J., and Tattersfield, A. E. (1977) b-adrenergic agonist resistance in normal human airways. Lancet 2, 375-377
25. Harvey, J. E. and Tattersfield, A. E. (1982) Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic and asthmatic subjects. Thorax 37, 280-287.
26. Kraan, J., Koeter, G. H., van der Mark, T. W., Sluiter, H., and de Vries, K. (1985), Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J. Allergy Clin. Immunol. 76, 628-636.
27. Vathenen, A. S., Knox, A. J., Higgins, B. G., Britton, J. R., and Tattersfield, A. E. (1988), Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet. I, 554-558.
28. 2-agonists treatment. Am. Rev. Respir Dis. 148, 707-712.
29. Cockcroft, D. W., McParland, C. P., Britton, S. A., Swystun, V. A., and Rutherford, B. C. (1993), Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 342, 833-837.
30. Szentivanyi, A. (1968) The beta-adrenergic theory of the atopic abnormality in bronchial asthma. J. Allergy 42, 203-232.
31. Assem, E. S. K. and Schild, H. O. (1969), Inhibition by sympathomimetic amines of histamine release induced by antigen in passively sensitized human lung. Nature 224, 1028-1029.
32. Howarth, P. H., Durham, S. R., Lee, T. H., Kay, A. B., Church, M. K., and Holgate, S. T. (1985), Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma. Am. Rev. Respir. Dis. 132, 986-992.
33. Barnes, P. J. (1995), Beta-adrenergic receptors and their regulation. Am. J. Respir. Crit. Care Med. 152, 838-860.
34. Sutherland, E. W. and Rall, T. W. (1960), The relation of adenosine-3,5-phosphate to the action of catecholamines and other hormones. Pharmac. Rev. 12, 265-299.
35. Robison, G. A., Butcher, R. W., and Sutherland, E. W. (1967) Adenyl cyclase as an adrenergic receptor. Ann. NY Acad. Sci. 139, 703-723.
36. 2-adrenergic receptor and homology with rhodopsin. Nature 321, 75-79.
37. Heaf, P. J. D. (1970), Deaths in asthma: a therapeutic misadventure. Br. Med. Bull. 26, 245-247.
38. Morrison Smith, J. (1966), Death from asthma. Lancet 1, 1042 (letter).
39. Greenberg, M. and Pines, A. (1968), Pressurised aerosols in asthma. Br. Med. J. 1, 563 (letter).
40. Inman, W. H. W. and Adelstein, A. M. (1969) Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols. Lancet ii, 279-285.
41. Stolley, P. D. (1972), Asthma mortality: why the United States was spared an epidemic of deaths due to asthma. Am. Rev. Respir. Dis. 105, 883-890.
42. Campbell, A. H. (1976), Mortality from asthma and bronchodilator aerosols. Med. J. Australia 1, 386-391.
43. Blauw, G. J. and Westendorp, R. G. J. (1995), Asthma deaths in New Zealand: whodunit? Lancet 345, 2-3.
44. Jackson, R. J., Beaglehole, R., Rea, H. H., and Sutherland, D. C. (1982), Mortality from asthma: a new epidemic in New Zealand. Br. Med. J. 285, 771-774.
45. Crane, J., Pearce, N., Flatt, A., et al. (1989), Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet I, 917-922.
46. Grainger, J., Woodman, K., Pearce, N., et al. (1991), Prescribed fenoterol and death from asthma in New Zealand, 1981-87: a further case-control study. Thorax 46, 105-111.
47. Crane, J, Burgess, C., and Beasley, R. (1989), Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol and isoprenaline. Thorax 44, 136-140.
48. Rona, G., Chappel, C. I., Balazs, T., and Gaudry, R. (1959), An infarct-like myocardial lesion and other toxic manifestations produced by isoproterenol in the rat. Arch. Pathol 67, 443-445.
49. Bremner, P., Burgess, C. D., Crane, J., et al. (1992) Cardiovascular effects of fenoterol under conditions of hypoxaemia. Thorax 47, 814-817.
50. Kiely, D. G., Cargill, R. I., and Lipworth, B. J. (1995), Cardiopulmonary interactions of salbutamol and hypoxaemia in healthy young volunteers. Br. J. Clin. Pharmacol. 40, 313-318.
51. Van Metre, T. E. (1969), Adverse effects of inhalation of excessive amounts of nebulised isoproterenol in status asthmaticus. J. Allergy 43, 101-113.
52. Reisman, R. E. (1970), Asthma induced by adrenergic aerosols. J. Allergy 46, 162-177.
53. Cockcroft, D. W. and Swysstun, V. A. (1997), Effect of S-Salbutamol, R-Salbutamol racemic Salbutamol and placebo on the airway response to methacholine. Thorax 52, 845-848.
54. 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Thorax 52, 849-852.
55. Paterson, J. W., Sudlow, M. F., and Walker, S. R. (1971), Blood levels of fluorinated hydrocarbons in asthmatic patients after inhalation of pressurised aerosols. Lancet 2, 565-568.
56. Dollery, C. T., Draffen, G. H., Davies, D. S., Williams, F. M., and Conolly, M. E. (1970). Blood concentrations in man of fluorinated hydrocarbons after inhalation of pressurised aerosols. Lancet 2, 1164-1166.
57. Sears, M. R., Taylor, D. R., Print, C. G., et al. (1990), Regular inhaled b-agonist treatment in bronchial asthma. Lancet 336, 1391-1396.
58. Harrison, T. W., Oborne, J., Wilding, P. J., and Tattersfield, A. E. (1999), Randomised placebo controlled trial of β-agonist dose reduction in asthma. Thorax 54, 98-102.
59. 2 adrenoceptor polymorphism. Thorax 55, 762-767.
60. 2-agonist therapy in asthma. Eur. Respir. J. 11, 589-593.
61. 2-adrenergic receptor on the response to regular use of albuterol in asthma. Am. J. Respir. Crit. Care. Med. 162, 75-80.
62. Israel, E., Chinchilli, V. M., Ford, J. G., et al. (2004), Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364, 1505-1512.
63. 2- adrenoceptor agonist. The comparative pharmacology of formoterol and salmeterol, in New Drugs in Allergy and Asthma. Barnes, P. J. ed., Birkhauser, Basel.
64. 2-agonists in the management of obstructive pulmonary disease. Drug Safety 27, 689-715.
65. Pauwels, R. A., Löfdahl, C-G., Postma, D. S., et al., for the Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. (1997), Effect of inhaled formoterol and budesonide on exacerbations of asthma. N. Engl. J. Med. 337, 1405-1411.
66. Pearlman, D. S., Chervinski, P., LaForce, C. et al. (1992), A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N. Engl. J. Med. 327, 1420-1425.
67. Greening, A. P., Ind, P. W., Northfield, M., and Shaw, G. (1994), Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 344, 219-224.
68. Nelson, H. S., Weiss, S. T., Bielker, E. R., Yancy, S. W., Dorinsky, P. M., and the SMART study group. (2006) The salmeterol multicenter asthma research trial. Chest 129, 15-26.